EGFR and colorectal carcinoma: In a recent work aimed at identifying biomarkers of sensitivity to anti-EGFR treatment [47], Schütte and co-workers proposed an experimental platform called OncoTrack (OT), derived from a large biobank of 106 CRC that includes 35 organoids and 59 PDXs, from which nineteen tumors were modelled in both systems.